Background: Metronomic chemotherapy consists of low-dose oral chemotherapy given continuously. The antitumor activity is supposed to be due to antiangiogenic and immunomodulation effects. This retrospective analysis was done to evaluate the benefit-risk balance of this treatment in palliative setting for unselected metastatic cancer patients.
Top
